Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00642499 · ClinicalTrials.gov registry record · Phase 2
Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting
A Phase 2 study of HIV Infections and Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
- 20
- Study locations
NCT00642499: Completed Phase 2 study of HIV Infections and Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting, sponsored by Solvay Pharmaceuticals.
NCT00642499 is a Phase 2 study of HIV Infections and Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting that has completed, run by Solvay Pharmaceuticals. The registered enrollment target is 103 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00642499, a Phase 2 study of HIV Infections and Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to determine if dronabinol is effective in preventing or treating nausea caused by HAART (highly active anti-retroviral therapy) in HIV and AIDS patients
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dronabinol
Study Locations (20)
Florida
- Site 907 - Altamonte Springs
- Site 948 - Miami
- Site 951 - Miami
- Site 953 - Miami
- Site 959 - Miami
- Site 954 - North Palm Beach
- Site 957 - Pensacola
- Site 923 - Port Saint Lucie
- Site 929 - Sarasota
- Site 952 - Tallahassee
- Site 931 - Tampa
California
- Site 911 - Bakersfield
- Site 919 - Fresno
- Site 924 - Los Angeles
- Site 932 - Los Angeles
- Site 926 - Palm Springs
- Site 946 - Pasadena
- Site 913 - Tarzana
Georgia
- Site 908 - Decatur
Idaho
- Site 905 - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2003-08 |
| Est. Completion | 2005-04 |
| Phase | Phase 2 |
What the finished NCT00642499 record still lists
NCT00642499 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00642499 names 20 study sites across 4 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT00642499 about?
NCT00642499 is a clinical study titled "Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting". The primary purpose of this study is to determine if dronabinol is effective in preventing or treating nausea caused by HAART (highly active anti-retroviral therapy) in HIV and AIDS patients
What is the current status of trial NCT00642499?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2003-08. Estimated completion is 2005-04.
What conditions does trial NCT00642499 study?
This clinical trial studies the following conditions: HIV Infections, Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting.
What interventions are being tested in trial NCT00642499?
The interventions under investigation include: Placebo (DRUG), Dronabinol (DRUG).
Who is sponsoring clinical trial NCT00642499?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00642499 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00642499's enrollment target sits among peer trials
103 261st of 542 higher than 281 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia